TMD8 Cells
USUSD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | The TMD8 cell line is a human diffuse large B-cell lymphoma (DLBCL) model representative of the activated B-cell-like (ABC) subtype. This subtype is characterized by constitutive activation of the NF-κB pathway, which is essential for cell survival. TMD8 exhibits wild-type CARD11, yet maintains strong NF-κB activity, indicating a dependency on chronic active B-cell receptor (BCR) signaling. This dependency is supported by experimental evidence showing that knockdown of BCR pathway components—including BTK, CD79A, CD79B, and IgM—leads to cell death in TMD8 cells. Additionally, TMD8 harbors a Y196H mutation in the ITAM domain of CD79B, a mutation commonly found in ABC-DLBCLs that enhances surface BCR expression and attenuates negative feedback from Lyn kinase, thus promoting sustained signaling activity. TMD8 cells also demonstrate notable sensitivity to BCL-2 inhibition via venetoclax when expressing high levels of the BCL-2 protein. However, resistance to venetoclax in such cells can be mediated by activation of the PI3K/AKT pathway, particularly following prolonged drug exposure. This resistance mechanism involves a reduction in PTEN expression and increased AKT phosphorylation. TMD8 cells with acquired resistance to venetoclax exhibit heightened susceptibility to pharmacological PI3K/AKT pathway inhibition, making them a suitable model for studying therapeutic combinations aimed at overcoming resistance in aggressive B-cell lymphomas. |
|---|---|
| 生物體 | Human |
| 組織 | Bone marrow |
| 疾病 | Diffuse large B-cell lymphoma activated B-cell type |
| 同義詞 | TMD-8, Tokyo Medical and Dental university 8 |
特徵
| 年齡 | 62 years |
|---|---|
| 性別 | Male |
| 族裔 | Japanese |
| 生長特性 | Suspension |
監管數據
| 引用 | TMD8 (Cytion catalog number 305729) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_A442 |
生物分子資料
| 突變譜 | Mutation: CD79B, Simple, p.Tyr196His (c.586T>C), Heterozygous, M yearsD88, Simple, p.Leu252Pro (c.755T>C) (L265P), Heterozygous |
|---|
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS |
| 倍增時間 | ~30 hours |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305729-280425 | 分析證明書 | 18. Aug. 2025 | 305729 |
| 305729-150925 | 分析證明書 | 05. Dec. 2025 | 305729 |